Solitary Plasmacytoma with Minimal Marrow Involvement

Khalife Mustapha*
Assistant professor of medicine oncology

*Corresponding author: Khalife Mustapha, Assistant professor of medicine oncology, USA

INTRODUCTION

Plasma cell dyscrasias belong to a group of malignancies characterized by the malignant proliferation of a single plasma cell clone. Plasma cell dyscrasias can present as a single lesion (solitary plasmacytoma with or without limited bone marrow involvement) or as multiple lesions (multiple myeloma) or as no detectable lesions (MGUS, smoldering myeloma or multiple myeloma). The reason why certain plasma cell neoplasms evolve into plasmacytoma and no other plasma cell dyscrasias including multiple myeloma is not quite understood. It is very important to differentiate these entities since their management, treatment and prognosis vary considerably.

DEFINITION

Solitary plasmacytoma is a plasma cell malignancy consisting of a localized, single clone of plasma cells in the absence of anemia, hypercalcemia, renal insufficiency, or multiple lytic bone lesions considered to be features of multiple myeloma.

CLINICAL PRESENTATION OF SOLITARY PLASMACYTOMA

Solitary plasmacytomas most commonly occur in bone and is referred to as solitary plasmacytoma of bone (SPB) also called osseous plasmacytoma. Solitary plasmacytomas less frequently occur in soft tissues and are referred to as extramedullary plasmacytoma.

Most patients with plasmacytomas present with pain (skeletal pain from a bone lesion or a pathologic fracture) or neurologic compromise (from cord compression). Less commonly, solitary plasmacytoma can present as a palpable mass (proliferation in soft tissue).

LABORATORY FINDINGS

Typically, patients with SPB have no anemia, renal failure, hypercalcemia or any additional lytic bone lesions. Approximately 60% of patients with SPB have no clonal plasma cells on bone marrow. However, about 40% of patients with apparent SPB have evidence of clonal plasma cells on bone marrow examination (typically less than 10%) and these are referred to as solitary plasmacytoma with limited bone marrow involvement [1].

TREATMENT

Most patients with solitary plasmacytoma will be staged as Durie-Salmon stage I myeloma. In the absence of end organ damage and if they have less than 10% clonal plasma cells in the bone marrow, these patients are considered to have solitary plasmacytoma with limited bone marrow involvement (or just solitary plasmacytoma in case of no monoclonal plasma cells in the bone marrow) and are typically treated with radiation.

If patients have more extensive clonal plasmacytosis in the bone marrow (more than 10%), systemic therapy can be considered, although there are limited data available to guide therapy.

PROGNOSIS

Patients with solitary plasmacytoma with limited bone marrow involvement are treated in a similar fashion to SPB but have a higher risk of progression to symptomatic myeloma with a 60% chance of recurrence or progression within three years [2,3].

DIFFERENTIAL DIAGNOSIS

It is important to distinguish SPB both from other diseases since management, prognosis is different. Patients with multiple...
myeloma typically have lytic lesions, anemia, hypercalcemia, and/or renal insufficiency. These patients also tend to have more than 10% plasma cell on bone marrow. Patients with POEMS syndrome (also referred to as osteosclerotic myeloma: Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal protein, Skin changes) typically present with peripheral neuropathy, osteosclerotic lesions, organomegaly, endocrinopathy (excluding diabetes mellitus or hypothyroidism), Castleman’s disease, typical skin changes, edema, and/or papilledema. These patients typically have elevated serum vascular endothelial growth factor (VEGF) levels.

References

